| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ABLAbacus Global Management, Inc. | 826.99M | 8.46 | -24.88 | 68.56% | 5.62% | 2.51% | 0.91 | |
| ABLLLAbacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 | 2.49B | 25.46 | -74.88 | 68.56% | 5.62% | 2.51% | 0.91 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Revenue | 1.22M | 22.59M | 44.71M | 66.4M | 111.92M |
| Revenue Growth % | - | 17.45% | 0.98% | 0.49% | 0.69% |
| Medical Costs & Claims | 514.67K | 14.21M | 5.88M | 6.49M | 11.37M |
| Medical Cost Ratio % | - | - | - | - | - |
| Gross Profit | 710.01K | 8.39M | 38.83M | 59.91M | 100.55M |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | 10.81% | 3.63% | 0.54% | 0.68% |
| Operating Expenses | -641.33K | 7.45M | 5.16M | 35.79M | 101.44M |
| OpEx / Revenue % | - | - | - | - | - |
| Depreciation & Amortization | 0 | 31.24K | 4.28K | 3.41M | 7.91M |
| Combined Ratio % | - | - | - | - | - |
| Operating Income | 1.35M | 937.12K | 33.67M | 24.13M | -888.3K |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -0.31% | 34.92% | -0.28% | -1.04% |
| EBITDA | 662.02K | 968.36K | 33.67M | 27.54M | 7.02M |
| EBITDA Margin % | - | - | - | - | - |
| Interest Expense | 0 | 0 | 42.8K | 9.87M | 18.28M |
| Non-Operating Income | 689.33K | -61.5K | 345.54K | 3.76M | 265.31K |
| Pretax Income | 662.02K | 998.62K | 33.28M | 10.5M | -19.43M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 1.56K | 1.2K | 889.94K | 1.47M | 5.48M |
| Effective Tax Rate % | - | - | - | - | - |
| Net Income | 662.02K | 997.41K | 31.68M | 9.52M | -23.96M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 0.51% | 30.76% | -0.7% | -3.52% |
| EPS (Diluted) | -0.25 | 0.37 | -0.02 | 0.16 | -0.34 |
| EPS Growth % | - | 2.48% | -1.06% | 8.34% | -3.13% |
| EPS (Basic) | -0.25 | 0.37 | -0.02 | 0.17 | -0.34 |
| Diluted Shares Outstanding | 43.13M | 43.13M | 29.55M | 57.77M | 70.76M |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Assets | 1.46M | 1.84M | 59.09M | 331.83M | 874.16M |
| Asset Growth % | - | 0.26% | 31.11% | 4.62% | 1.63% |
| Total Investment Assets | 1.25M | 1.5M | 3.19M | 129.1M | 375.54M |
| Long-Term Investments | 1.25M | 1.5M | 3.19M | 126.85M | 375.54M |
| Short-Term Investments | 0 | 0 | 0 | 2.25M | 0 |
| Total Current Assets | 211.2K | 194.82K | 33.28M | 31.78M | 159.56M |
| Cash & Equivalents | 135.27K | 102.42K | 30.05M | 25.59M | 131.94M |
| Receivables | 0 | 0 | 208.81K | 1000K | 1000K |
| Other Current Assets | 74.76K | 67.49K | 2.9M | 699.13K | 1.09M |
| Goodwill & Intangibles | 0 | 0 | 0 | 169.91M | 318.08M |
| Goodwill | 0 | 0 | 0 | 140.29M | 238.3M |
| Intangible Assets | 0 | 0 | 0 | 29.62M | 79.79M |
| PP&E (Net) | 0 | 145.4K | 95.63K | 2.29M | 5.75M |
| Other Assets | 0 | 0 | 22.53M | 998.95K | 15.23M |
| Total Liabilities | 160.7K | 1.07M | 30.95M | 167.76M | 450.87M |
| Total Debt | 148.97K | 1.05M | 28.59M | 141.74M | 385.91M |
| Net Debt | 13.7K | 950.71K | -1.46M | 116.15M | 253.97M |
| Long-Term Debt | 0 | 0 | 28.25M | 126.79M | 342.39M |
| Short-Term Debt | 148.97K | 930.63K | 263.79K | 13.03M | 38.43M |
| Total Current Liabilities | 160.7K | 995.93K | 1.3M | 23.33M | 62.47M |
| Accounts Payable | 0 | 0 | 40.01K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 507K | 2.47M |
| Other Current Liabilities | 11.73K | 20.19K | 950.48K | 3.4M | 14.42M |
| Deferred Taxes | 0 | 0 | 0 | 1000K | 1000K |
| Other Liabilities | 0 | 0 | 1.36M | 6.64M | 14.66M |
| Total Equity | 1.3M | 766.89K | 28.15M | 164.07M | 423.29M |
| Equity Growth % | - | -0.41% | 35.71% | 4.83% | 1.58% |
| Shareholders Equity | 1.3M | 915.05K | 27.25M | 163.93M | 424.15M |
| Minority Interest | 0 | -148.16K | 899.54K | 138.28K | -857.83K |
| Retained Earnings | 590.5K | 205.05K | 25.49M | -34.73M | -57.9M |
| Common Stock | 50K | 50K | 5.04K | 6.34K | 10.13K |
| Accumulated OCI | 0 | 0 | 1.05M | 108.37K | 0 |
| Return on Equity (ROE) | 0.51% | 0.96% | 2.19% | 0.1% | -0.08% |
| Return on Assets (ROA) | 0.45% | 0.6% | 1.04% | 0.05% | -0.04% |
| Equity / Assets | - | - | - | - | - |
| Debt / Equity | 0.11x | 1.37x | 1.02x | 0.86x | 0.91x |
| Book Value per Share | 0.03 | 0.02 | 0.95 | 2.84 | 5.98 |
| Tangible BV per Share | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | 650.13K | 1.34M | -2.6M | -64.52M | -208.81M |
| Operating CF Growth % | - | 1.07% | -2.94% | -23.79% | -2.24% |
| Operating CF / Revenue % | - | - | - | - | - |
| Net Income | 662.02K | 997.41K | -643.56K | 9.03M | -23.96M |
| Depreciation & Amortization | 0 | 31.24K | 4.28K | 3.41M | 7.91M |
| Stock-Based Compensation | 0 | 0 | 0 | 10.77M | 43.44M |
| Deferred Taxes | 0 | 0 | 889.94K | 466.58K | 6M |
| Other Non-Cash Items | 0 | 0 | 15.13M | -18.47M | -46.47M |
| Working Capital Changes | -11.88K | 314.1K | -17.98M | -69.73M | -195.73M |
| Cash from Investing | -1.25M | -241.53K | 246.5M | 2.24M | -4.96M |
| Capital Expenditures | 0 | -226.66K | -79.1K | -189.67K | -805.14K |
| Acquisitions | 16.4K | -14.86K | 0 | 0 | -2.43M |
| Purchase of Investments | -1.25M | -250K | -1.92M | -350K | -1.2M |
| Sale/Maturity of Investments | 0 | 0 | 1000K | 0 | 0 |
| Other Investing | -16.4K | 250K | 79.1K | 2.78M | -519.53K |
| Cash from Financing | 697.81K | -354.58K | -244.66M | 57.82M | 320.12M |
| Dividends Paid | -327.8K | -358.22K | -659.36K | 0 | 0 |
| Share Repurchases | 0 | 0 | -6.4M | -24.82M | -10.74M |
| Stock Issued | 0 | 0 | 0 | 972.26K | 181.7M |
| Debt Issuance (Net) | 0 | 0 | 1000K | 1000K | 1000K |
| Other Financing | 1.03M | 3.64K | -25.94M | -38.84M | -17.08M |
| Net Change in Cash | 97.95K | 746.66K | -766.56K | 25.5M | 106.36M |
| Exchange Rate Effect | 0 | 0 | 0 | 1000K | 0 |
| Cash at Beginning | 37.33K | 1.85M | 853.13K | 86.57K | 25.59M |
| Cash at End | 135.27K | 2.6M | 86.57K | 25.59M | 131.94M |
| Free Cash Flow | 650.13K | 1.12M | -2.68M | -64.71M | -209.62M |
| FCF Growth % | - | 0.72% | -3.4% | -23.13% | -2.24% |
| FCF Margin % | - | - | - | - | - |
| FCF per Share | 0.02 | 0.03 | -0.09 | -1.12 | -2.96 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Combined Ratio | -10.34% | 95.85% | 24.71% | 63.67% | 100.79% |
| Medical Cost Ratio | 42.02% | 62.88% | 13.16% | 9.77% | 10.16% |
| Return on Equity (ROE) | 50.91% | 96.49% | 219.13% | 9.9% | -8.16% |
| Return on Assets (ROA) | 45.31% | 60.42% | 103.99% | 4.87% | -3.97% |
| Equity / Assets | 89% | 41.67% | 47.63% | 49.44% | 48.42% |
| Book Value / Share | 0.03 | 0.02 | 0.95 | 2.84 | 5.98 |
| Debt / Equity | 0.11x | 1.37x | 1.02x | 0.86x | 0.91x |
| Revenue Growth | - | 1744.73% | 97.92% | 48.5% | 68.56% |
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) grew revenue by 68.6% over the past year. This is strong growth.
Yes, Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) is profitable, generating $11.0M in net income for fiscal year 2024 (-21.4% net margin).
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) has a combined ratio of 100.8%. A ratio above 100% means claims and expenses exceed premiums.